Candel Therapeutics/$CADL
1D1W1MYTD1Y5YMAX
Capital at risk
About Candel Therapeutics
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
- Ticker
- $CADL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 55
- Headquarters
- Needham, United States
- Website
- www.candeltx.com
CADL Metrics
BasicAdvanced
$817M
-
-$1.44
-0.50
-
Price and volume
Market cap
$817M
Beta
-0.5
52-week high
$14.00
52-week low
$4.35
Average daily volume
1.3M
Financial strength
Current ratio
16.094
Quick ratio
15.89
Long term debt to equity
0.389
Total debt to equity
0.393
Interest coverage (TTM)
-15.26%
Profitability
EBITDA (TTM)
-71.303
Management effectiveness
Return on assets (TTM)
-28.64%
Return on equity (TTM)
-81.84%
Valuation
Price to book
6.44
Price to tangible book (TTM)
6.44
Price to free cash flow (TTM)
-11.473
Free cash flow yield (TTM)
-8.72%
Free cash flow per share (TTM)
-0.93
Growth
Earnings per share change (TTM)
175.63%
3-year earnings per share growth (CAGR)
8.93%
Bulls say / Bears say
The lead prostate-cancer program has meaningful late-stage validation: after a median 58-month follow-up in 745 patients, aglatimagene showed a 39% improvement in prostate-cancer-specific disease-free survival versus placebo, with no new safety signals reported. (Candel Therapeutics)
Candel initiated the global Phase 3 AURORA trial in NSCLC, supported by encouraging Phase 2a follow-up in which 50% of 46 per-protocol patients survived beyond 24 months and median overall survival was 25.4 months in evaluable patients. (Candel Therapeutics)
The balance sheet provides substantial near-term execution capacity: Candel reported $201.6 million of cash and equivalents at June 30, 2026, expects funding into Q1 2028, and has added EVERSANA plus an experienced chief commercial officer ahead of a potential 2027 launch. (Candel Therapeutics)
Candel remains dependent on regulatory execution: aglatimagene is not approved for any indication, while the prostate-cancer BLA is only planned for Q4 2026 and the NSCLC program is still in Phase 3. (Candel Therapeutics)
Cash consumption is accelerating as the company advances pivotal trials and manufacturing: Q2 2026 R&D expense rose to $19.8 million from $7.0 million, G&A increased to $6.9 million from $4.2 million, and net loss widened to $38.9 million from $4.8 million. (Candel Therapeutics)
Financing has increased potential shareholder and future-revenue dilution: Candel sold approximately $100 million of stock in February 2026 and entered a royalty deal that gives RTW a tiered single-digit percentage of U.S. aglatimagene sales, subject to a cap. (Candel Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 11 Sept 2026.
Upcoming events
No upcoming events
CADL News
AllArticlesVideos
Funds containing CADL
AllUSDGBPEUR
Fund name | Fund size | $CADL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.